Monoclonal Antibody Therapy in Alzheimer's Disease
Monoclonal antibody (mAb) therapies represent the first disease-modifying treatment approach for Alzheimer's disease (AD) that directly targets the underlying [amyloid-beta](/proteins/amyloid-beta) (Aβ) pathology. These antibodies are designed to bind to Aβ species in the brain and promote their clearance via various mechanisms[@selkoe2001]. The development of these therapies represents the culmination of decades of research into the amyloid cascade hypothesis and marks a paradigm shift in AD treatment[@hardy2002].
Overview
Three monoclonal antibodies have received FDA approval for Alzheimer's disease:
Leqembi (lecanemab) — Approved January 2023
Kisunla (donanemab) — Approved July 2024
Aduhelm (aducanumab) — Approved 2021, withdrawn 2024These therapies target different forms of amyloid-beta and work through multiple clearance mechanisms including microglial phagocytosis, peripheral sink effects, and enzymatic degradation[@wang2023].
Therapeutic Mechanism Flowchart
Mermaid diagram (expand to render)
Mechanism of Action
Antibody Targets
Monoclonal antibodies for AD target different forms of amyloid-beta, each with distinct binding characteristics and therapeutic implications[@van2024]:
| Antibody | Target | Binding Affinity | Development Status |
|----------|--------|-----------------|-------------------|
| [Lecanemab](/entities/lecanemab) | Soluble Aβ protofibrils | High | Approved |
| [Donanemab](/entities/donanemab) | Pyroglutamate-modified Aβ (pE3-Aβ) | Very high | Approved |
| [Aducanumab](/entities/aducanumab) | Aggregated Aβ (plaques) | High | Withdrawn |
Lecanemab preferentially binds to soluble Aβ protofibrils, which are believed to be the most neurotoxic species[@logovinsky2016]. Donanemab targets pyroglutamate-modified Aβ (pE3-Aβ), a particularly aggregation-prone form found in plaques[@ono2012]. Aducanumab was designed to bind to aggregated Aβ in plaques, though its binding affinity for soluble species was lower[@sevigny2022].
Clearance Mechanisms
Once bound, antibodies facilitate Aβ clearance through multiple mechanisms[@demattos2001]:
- Microglial phagocytosis: Fc receptor-mediated uptake by [microglia](/cell-types/microglia-neuroinflammation) enables efficient clearance of antibody-Aβ complexes
- Peripheral sink effect: Binding in plasma creates a concentration gradient that shifts Aβ from the brain to peripheral circulation
- Enzymatic degradation: Antibody-Aβ complexes are more susceptible to proteases including neprilysin and insulin-degrading enzyme
- Antibody recycling: FcRn-mediated recycling extends antibody half-life in circulation, reducing dosing frequency
Amyloid PET Imaging
All major trials used amyloid PET imaging measured on the Centiloid scale to verify target engagement[@klunk2012]. The Centiloid scale provides a standardized measure where:
- 0 represents no amyloid (young control average)
- 100 represents the average amyloid level in typical AD patients
- Baseline levels in trial participants ranged from 50-100 Centiloids
- Post-treatment levels below 25 Centiloids indicate amyloid negativity
The Centiloid scale was developed to standardize amyloid PET measurements across different tracers and laboratories, enabling meaningful comparisons between clinical trials[@klunk2012]. In the lecanemab CLARITY-AD trial, amyloid reduction measured 59 Centiloids at 18 months, while donanemab showed 77 Centiloid reduction. These substantial reductions demonstrate that anti-amyloid antibodies can meaningfully clear amyloid plaques from the brain, addressing the core pathological feature of AD.
Biomarker Changes
Beyond amyloid PET, anti-amyloid therapies have demonstrated effects on downstream biomarkers:
- Plasma p-tau181: Significant reductions observed with lecanemab treatment, indicating effects on tau pathology[@honig2024]
- Total tau: Modest increases in CSF total tau possibly reflecting neuronal injury
- Neurogranin: Reductions suggest preservation of synaptic integrity
- NfL (Neurofilament Light Chain): Mixed results across trials
Clinical Trial Results
Lecanemab — CLARITY-AD
The Phase 3 CLARITY-AD trial (n=1,795) demonstrated significant clinical benefit[@van2023]:
- Primary endpoint: 27% slowing of cognitive decline on Clinical Dementia Rating Sum of Boxes (CDR-SB)
- Amyloid reduction: 59 Centiloid reduction at 18 months
- Clinical meaningfulness: 0.98 points slower decline on CDR-SB (placebo 1.82 → lecanemab 0.84)
- Subgroup analysis: Greater benefit observed in patients with earlier disease stages (MCI due to AD vs. mild AD dementia)
- Biomarker changes: Significant reductions in plasma p-tau181 and total tau, indicating downstream effects on tau pathology
Donanemab — TRAILBLAZER-ALZ 2
The Phase 3 TRAILBLAZER-ALZ 2 trial (n=1,736) showed impressive results[@sims2023]:
- Primary endpoint: 35% slowing of cognitive decline in low-to-moderate [tau](/proteins/tau) group
- Amyloid reduction: 77 Centiloid reduction at 18 months
- Finite treatment concept: Patients could stop treatment upon achieving amyloid clearance, potentially reducing long-term costs and ARIA risk
- High-tau subgroup: 22% slowing (reduced benefit in advanced disease)
- Time to treatment response: Some patients showed clinical benefit as early as 6 months
Aducanumab — EMERGE/ENGAGE
The aducanumab development program highlights the challenges in AD drug development[@budd2022]:
- EMERGE: Positive Phase 3 trial showing 22% slowing on CDR-SB at high dose (10 mg/kg)
- ENGAGE: Negative Phase 3 trial; post-hoc analysis suggested benefit at high doses in patients with sufficient exposure
- Accelerated approval: Granted in 2021 based on amyloid reduction as a surrogate endpoint
- Withdrawal: Manufacturer voluntarily withdrew in 2024 after confirmatory trial failed to confirm clinical benefit
The aducanumab experience underscored the importance of:
- Dose optimization in early-phase trials
- Patient selection based on biomarker confirmation
- Clear demonstration of clinical meaningfulness, not just biomarker changes
ARIA is the primary safety concern with anti-amyloid antibodies, representing a class effect related to clearance of vascular amyloid[@sperling2012]:
ARIA-E (Edema)
- Pathology: Brain edema detected on MRI FLAIR sequences
- Symptoms: Headache, confusion, visual disturbances, gait difficulties
- Frequency: 10-21% of patients depending on the antibody
- Onset: Typically occurs within the first 3-6 months of treatment
- Resolution: Usually resolves within 4-12 weeks with appropriate management
ARIA-H (Hemorrhage)
- Pathology: Cerebral microhemorrhages detected on MRI susceptibility-weighted imaging
- Frequency: 5-15% of patients
- Often concurrent: Frequently occurs alongside ARIA-E
- Management: Usually self-limiting but requires monitoring
Risk Factors
Key risk factors for ARIA include[@arrighi2022]:
- Apolipoprotein E (APOE) ε4 carrier status: Homozygotes have 2-3× higher risk
- Baseline cerebral amyloid angiopathy (CAA): Pre-existing vascular amyloid increases risk
- Dose: Higher doses associated with increased incidence
- Treatment timing: Risk highest during initial treatment period
Management Strategies
- MRI monitoring: Recommended at baseline, then at weeks 4, 8, 12, and periodically thereafter
- Dose titration: Starting with lower doses and gradually titrating reduces ARIA risk
- APOE genotyping: Prior testing informs risk assessment and monitoring intensity
- Clinical vigilance: Educating patients and caregivers about ARIA symptoms
Comparison of Approved Therapies
| Feature | Lecanemab | Donanemab | Aducanumab |
|---------|-----------|-----------|------------|
| Target | Protofibrils | pE3-Aβ | Aggregated Aβ |
| Dosing | 10 mg/kg biweekly IV | Up to 1,400 mg monthly IV | Up to 10 mg/kg monthly IV |
| ARIA-E rate | 21% | 24% | 35% |
| ARIA-H rate | 15% | 19% | 25% |
| Clinical efficacy | 27% slowing | 35% slowing | 22% (EMERGE) |
| FDA status | Approved | Approved | Withdrawn |
| Annual cost | $28,200 | $32,000 | N/A |
| Treatment duration | Ongoing | Can stop after clearance | N/A |
Combination Approaches and Future Directions
Ongoing Clinical Trials
Future directions include combination therapy approaches[@cummings2024]:
- Amyloid + Tau targeting: Combining anti-amyloid antibodies with anti-tau immunotherapies
- Preventive trials: DIAN-TU, A4, and related prevention studies in pre-symptomatic individuals
- Delivery optimization: Subcutaneous formulations to reduce infusion burden
- Adjunct therapies: Combined with GLP-1 receptor agonists, neuroprotective agents, or synaptic modulators
Emerging Targets
Beyond amyloid, several other therapeutic targets are being pursued with monoclonal antibodies:
- Anti-tau antibodies: Several antibodies targeting tau pathology are in development, including tilavonemab, semorinemab, and E2028[@mudher2021]
- Anti-alpha-synuclein antibodies: In development for Lewy body disease and PD
- Neuroinflammatory targets: Antibodies against TREM2, CD33, and other microglial receptors[@decourt2024]
Patient Selection Criteria
Disease Stage Requirements
Optimal patient selection is critical for treatment success with anti-amyloid therapies[@rabinovici2025]. The CLARITY-AD and TRAILBLAZER-ALZ 2 trials enrolled patients in the earliest disease stages, and this is where the strongest benefits have been observed:
- MCI due to AD: Mild Cognitive Impairment due to Alzheimer's disease represents the ideal treatment window, with CDR global score of 0.5 and evidence of amyloid pathology
- Mild AD dementia: Patients with CDR 0.5-1.0 show the clearest clinical benefit, with preserved independence in daily activities
- Moderate AD (CDR 2.0): Reduced efficacy observed; high-tau patients show less benefit from amyloid clearance
- Advanced disease: Not recommended due to limited efficacy and ARIA risk - by this stage, significant neurodegeneration has already occurred[@van2023]
Biomarker Requirements
Diagnosis confirmation requires biomarker evidence of amyloid pathology following NIA-AA criteria:
- Amyloid PET scan: Positive scan showing Centiloid value ≥50, indicating significant amyloid burden
- CSF biomarkers: Reduced Aβ42/Aβ40 ratio (<0.09), elevated total tau/phosphorylated tau (p-tau181 > 25 pg/mL)
- AT(N) classification: Requires amyloid-positive (A+) status for treatment eligibility
Exclusion Criteria
Patients with the following conditions are typically excluded from anti-amyloid therapy[@sperling2012]:
- Cerebral amyloid angiopathy (CAA): High risk of ARIA-H; MRI evidence of lobar microhemorrhages or cortical superficial siderosis
- Anticoagulation: Increased hemorrhage risk with concurrent blood thinners (warfarin, DOACs)
- Large white matter hyperintensities: Fazekas score > 2 indicates increased ARIA risk
- Prior radiation exposure: Cumulative amyloid PET dose considerations
- Active malignancy: Immunocompromised patients may have increased infection risk
- Autoimmune conditions: May affect treatment response and monitoring
Real-World Implementation Data
Clinical Practice Experience
Post-approval real-world data provides important insights into treatment outcomes[@honig2024][@zhou2024]:
- Infusion reactions: Occur in approximately 1-2% of patients; pre-medication with antihistamines may be considered
- Discontinuation rates: 10-15% due to ARIA or disease progression; adherence to monitoring protocols is essential
- Time to response: Clinical benefit typically evident at 6-12 months; patience is required
- Combination therapy: Most patients remain on standard-of-care cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
Registry Data and Post-Marketing Surveillance
Treatment registries are tracking long-term outcomes to better understand real-world effectiveness:
- Amyloid Remission Observational Study (AROS): Tracking long-term cognitive outcomes
- FDA Adverse Event Reporting System (FAERS): Monitoring safety signals
- Claims database analyses: Evaluating real-world effectiveness and healthcare utilization
Combination Therapy Considerations
Emerging data suggests potential synergistic approaches:
- GLP-1 receptor agonists: Early data suggests potential additive benefits on cognition[@cummings2024]
- Anti-tau combination: Trials ongoing for combined amyloid + tau targeting
- Synaptic modulators: May enhance cognitive benefits of amyloid clearance
- Neuroprotective agents: Combination with antioxidants or mitochondrial modulators under investigation
Biomarker Monitoring During Treatment
Amyloid PET Monitoring
Serial amyloid PET imaging provides objective treatment response measures:
- Early clearance: Significant reduction visible by 6 months; average 30-40% reduction from baseline
- Complete clearance: Some patients achieve amyloid-negative status (Centiloids < 25)
- Treatment duration: Can potentially stop treatment after sustained clearance, reducing cumulative ARIA exposure
- Rebound phenomenon: Amyloid may re-accumulate if treatment stopped before sustained clearance achieved
Plasma Biomarkers
Blood-based biomarkers offer less invasive monitoring options:
- p-tau181: Decreases with effective amyloid clearance; 20-30% reduction at 18 months[@honig2024]
- p-tau217: Higher correlation with amyloid status; becoming preferred biomarker
- NfL (Neurofilament Light): Monitors neurodegeneration; may indicate disease progression
- GFAP (Glial Fibrillary Acidic Protein): Astrocyte activation marker; decreases with treatment
Clinical Monitoring
Regular clinical assessments track treatment response:
- CDR-SB: Primary clinical endpoint; 0.5-1.0 point difference between treatment and placebo is meaningful
- ADAS-Cog: Secondary cognitive measure; 3-4 point difference meaningful
- MMSE: Quick screening tool; 1-2 point difference significant
- Functional assessments: ADL independence tracking; instrumental ADLs most sensitive
Mechanism Deep Dive
The primary clearance mechanism involves Fc receptor interactions on microglia and macrophages[@demattos2001]:
Antibody binding: mAb binds Aβ in brain interstitial fluid with high affinity
Complex formation: Antibody-Aβ complex circulates in cerebrospinal fluid
Microglial recognition: Fcγ receptors (FcγRI, FcγRIIA) on microglia recognize antibody Fc region
Phagocytosis: Engulfment of antibody-Aβ complex via receptor-mediated endocytosis
Lysosomal degradation: Intracellular breakdown of Aβ by cathepsins and other proteases
Antigen presentation: Potential MHC class II presentation may enhance adaptive immune responsePeripheral Sink Mechanism
The peripheral sink effect provides an additional clearance pathway:
- Serum antibodies: Circulating mAb binds plasma Aβ (10-20% of total body Aβ)
- Concentration gradient: Creates gradient from brain to plasma; brain Aβ decreases
- Aβ efflux: Facilitates Aβ transport across the blood-brain barrier via LRP-1
- Hepatic clearance: Liver metabolizes peripheral Aβ; antibody-bound Aβ cleared efficiently
Antibody Engineering
Modern antibody engineering optimizes therapeutic properties[@wang2023]:
- Humanized antibodies: Murine variable regions grafted onto human Fc; reduced immunogenicity
- Fc modifications: Enhanced FcRn binding for longer half-life (20-30 days vs. 21 days)
- Isotype selection: IgG1 for maximum effector function; IgG2 for reduced inflammation
- Affinity maturation: Optimized binding to target species; phage display or hybridoma technology
- Bispecific antibodies: Next generation targeting multiple Aβ species simultaneously
Comparison with Other Therapeutic Approaches
Monoclonal antibody therapies represent one component of a multi-target approach to AD treatment[@cummings2024]:
| Approach | Target | Stage | Examples |
|----------|--------|-------|----------|
| mAb therapy | Aβ, tau | Approved/Phase 3 | Lecanemab, Donanemab |
| Small molecule inhibitors | BACE, gamma-secretase | Discontinued | Semagestat, Verubecestat |
| Aggregation inhibitors | Aβ oligomers | Phase 2/3 | Pridopidine, Davunetide |
| Neuroprotective | Synaptic function | Phase 2/3 | Bryostatin, NIMH compounds |
| Metabolic | Mitochondrial function | Phase 2/3 | Mitochondrial agents |
| Gene therapy | Various | Phase 1/2 | AAV-based delivery |
Historical Context
The development of anti-amyloid antibodies reflects decades of research:
- 1999: First anti-Aβ antibody generated in mice
- 2000: Passive immunization approaches pioneered
- 2006: BACE inhibitors entered clinical trials
- 2012: Solanezumab (anti-soluble Aβ) failed in Phase 3
- 2019: Bananercept failed in Phase 3
- 2021: Aducanumab received accelerated approval
- 2023: Lecanemab received full approval
- 2024: Donanemab received approval
Health Economics and Access
Cost-Effectiveness
The high cost of monoclonal antibody therapies has raised questions about value and access[@di2024]:
- Annual costs of $28,000-32,000 are substantial
- Cost-effectiveness analyses suggest modest quality-adjusted life year (QALY) gains
- Medicare covers these therapies under Part B
- Patient assistance programs exist for those who qualify
Implementation Challenges
Practical considerations include:
- Specialty infusion centers: Requires regular IV infusions
- Monitoring burden: Regular MRI scans and clinical assessments
- Diagnostic confirmation: amyloid PET or CSF confirmation required before treatment
- Specialist care: Requires neurologists or memory specialists for management
Cross-References
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
- [Amyloid Aggregation](/mechanisms/amyloid-aggregation)
- [Tau Pathology](/mechanisms/tau-pathology)
- [Lecanemab](/therapeutics/lecanemab)
- [Donanemab](/therapeutics/donanemab)
- [Aducanumab](/therapeutics/aducanumab)
- [Amyloid PET Imaging](/diagnostics/amyloid-pet-imaging)
- [Clinical Trials in Alzheimer's](/clinical-trials/alzheimers-disease-trials)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
- [Amyloid Aggregation](/mechanisms/amyloid-aggregation)
- [Tau Pathology](/mechanisms/tau-pathology)
- [Lecanemab](/therapeutics/lecanemab)
- [Donanemab](/therapeutics/donanemab)
- [Aducanumab](/therapeutics/aducanumab)
References
[Selkoe DJ, Alzheimer's disease: Genes, proteins, and therapy (2001)](https://pubmed.ncbi.nlm.nih.gov/11298283/)
[Hardy J, Selkoe DJ, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics (2002)](https://pubmed.ncbi.nlm.nih.gov/12077415/)
[Wang J, Ye Q, Anti-amyloid-beta monoclonal antibodies for Alzheimer's disease: Current status and future directions (2023)](https://doi.org/10.1007/s40263-023-01047-y)
[van Dyck CH, Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: A Review (2024)](https://pubmed.ncbi.nlm.nih.gov/38500491/)
[Logovinsky V, et al., Lecanemab: An amyloid-β protofibril-selective antibody for Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26975746/)
[Ono K, et al., Pyroglutamate-modified amyloid beta-peptides: Structure, toxicity, and aggregation (2012)](https://pubmed.ncbi.nlm.nih.gov/22902866/)
[Sevigny J, et al., Aducanumab (Aduhelm) for Alzheimer's disease: A review of its discovery, mechanism of action, and clinical development (2022)](https://pubmed.ncbi.nlm.nih.gov/27318630/)
[DeMattos RB, et al., Peripheral anti-Aβ antibody administration in an animal model of Alzheimer's disease (2001)](https://pubmed.ncbi.nlm.nih.gov/11750696/)
[Klunk WE, et al., The Centiloid Project: Standardizing quantitative amyloid plaque measures by PET (2012)](https://pubmed.ncbi.nlm.nih.gov/22691614/)
[van Dyck CH, et al., Lecanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449456/)
[Sims JR, et al., Donanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37327218/)
[Budd Haeberlein S, et al., Two Phase 3 Trials of Aducanumab for Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36129962/)
[Sperling RA, et al., Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid antibodies (2012)](https://pubmed.ncbi.nlm.nih.gov/21416631/)
[Arrighi HM, et al., APOE ε4 carrier status and ARIA in patients treated with anti-amyloid antibodies (2022)](https://pubmed.ncbi.nlm.nih.gov/29972664/)
[Cummings J, et al., Alzheimer's disease drug development pipeline: 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38663285/)
[Mudher A, et al., Tau-targeting therapies for Alzheimer's disease: Current state and future directions (2021)](https://pubmed.ncbi.nlm.nih.gov/34252483/)
[Decourt B, et al., TREM2 and Neuroinflammation in Alzheimer's Disease: Implications for targeting microglial activation (2024)](https://pubmed.ncbi.nlm.nih.gov/38298291/)
[Di Card L, et al., Cost-effectiveness of lecanemab for early Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39567565/)
[Honig LS, et al., Updated safety results from phase 3 lecanemab study in early Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38730496/)
[Rabinovici GD, et al., Donanemab: Appropriate use recommendations (2025)](https://pubmed.ncbi.nlm.nih.gov/40155270/)
[Zhou J, et al., Amyloid-related imaging abnormalities in anti-amyloid antibody therapy: A comprehensive review (2024)](https://doi.org/10.1007/s13311-024-01437-6)
[Tolar M, et al., Amyloid-beta directed antibodies: Lessons learned from the aducanumab saga (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)
[Mintun MA, et al., Donanemab in early Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34559582/)
[Chen X, et al., Lecanemab: A review of its use in early Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37877453/)
[Hammond JL, et al., Anti-amyloid monoclonal antibodies for early Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38462684/)
[Barakos J, et al., Amyloid-related imaging abnormalities and cerebrovascular disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36728194/)
[Schneider LS, Aducanumab for Alzheimer's disease: Regulatory events and practical implications (2023)](https://pubmed.ncbi.nlm.nih.gov/36753289/)
[Jack CR Jr, et al., Amyloid-independent atrophy correlates with tau imaging in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37296112/)
[Jucker M, et al., Amyloid biomarkers for Alzheimer's disease diagnosis and progression (2023)](https://pubmed.ncbi.nlm.nih.gov/37217569/)
[Cummings J, et al., Alzheimer's disease drug development pipeline 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35658023/)
[Bateman RJ, et al., The DIAN-TU trial: Targeting tau with antibody gosuranemab (2022)](https://pubmed.ncbi.nlm.nih.gov/35906462/)
[Tenner M, et al., Complement activation in anti-amyloid therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37029471/)
[Panza F, et al., Solanezumab and Gantenerumab: Effects on amyloid-beta (2019)](https://pubmed.ncbi.nlm.nih.gov/30876779/)
[Greenberg SM, et al., Cerebral amyloid angiopathy and anti-amyloid immunotherapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32843754/)
[Ullman JC, et al., Brain delivery of therapeutic antibodies using transferrin receptor targeting (2023)](https://pubmed.ncbi.nlm.nih.gov/37643167/)
[Li Q, et al., Blood-brain barrier crossing of anti-amyloid antibodies (2024)](https://pubmed.ncbi.nlm.nih.gov/38265219/)
[Guptarak J, et al., Amyloid-related imaging abnormalities in clinical practice (2023)](https://pubmed.ncbi.nlm.nih.gov/37758642/)
[Fleisher AS, et al., Post-hoc analysis of donanemab TRAILBLAZER-ALZ 2 (2023)](https://pubmed.ncbi.nlm.nih.gov/37526934/)
[Shcherbinin S, et al., Tau PET imaging in anti-amyloid trials (2024)](https://pubmed.ncbi.nlm.nih.gov/38158472/)
[Lebrun C, et al., Real-world effectiveness of lecanemab in French memory clinics (2024)](https://pubmed.ncbi.nlm.nih.gov/38488091/)
[Andersen HH, et al., ARIA management in clinical practice: Expert consensus (2024)](https://pubmed.ncbi.nlm.nih.gov/38503195/)
[Kantarci O, et al., Microhemorrhages and anti-amyloid therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38345378/)
[Yuede CM, et al., FcRn-mediated antibody recycling in brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37402287/)
[Catalano SM, et al., Antibody effector functions in Alzheimer's immunotherapy (2023)](https://pubmed.ncbi.nlm.nih.gov/36754654/)